MiNK Therapeutics, Inc. (INKT)
(Real Time Quote from BATS)
$0.78 USD
+0.01 (0.65%)
Updated Sep 12, 2024 01:28 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
MiNK Therapeutics, Inc. [INKT]
Reports for Purchase
Showing records 1 - 14 ( 14 total )
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Recap: Initial Data From 2L Gastric Study to Be Presented at an Upcoming Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: Phase 2 Gastric Study Is Enrolling Patients Quickly With Initial Data Guided to 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Recap: Phase 2 Gastric Study Is Now in Full Swing
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: Gastric Cancer Phase 2 Study to Initiate in 4Q23; New SITC Data Add More POC for Combo Approach
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Recap: 2L Gastric Study to Commence in 3Q23; Additional Data Updates Expected 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MiNK-215 Preclinical Data at ASGCT Highlight Potential For CAR-iNKTs to Treat Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Recap: AgenT-797 Gastric Study and NSCLC Expansion Cohort to Initiate Shortly
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Response Noted in Gastric Cancer Patient Unlikely to Respond to PD-1; Expansion Cohorts to Initiate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Followed by KOL Call to Discuss agenT-797 (allo-iNKTs) Solid Tumor Data Update at AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Take: agenT-797 Solid Tumor Data Update at AACR to Be a Significant Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Noteworthy Discussion Points From Our Meetings at
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple SITC Updates Point to Early Though Encouraging Data; Pipeline Advances With Two New CAR-iNKT Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Take: Event Week Ahead With Multiple SITC Data Presentations; We Believe Expectations For Data Remain Low
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: MiNK Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dual Innate and Adaptive Immunity May Change the Cell Therapy Landscape for Solid Tumors; Initiate at Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
|